Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours

Jill E. Kucab(University of British Columbia), Sandra E. Dunn(University of British Columbia)

Breast Cancer Research

August 1, 2005

10.1186/bcr1294

Cited by 93

Related Papers

A Compendium of Mutational Signatures of Environmental Agents

|Cell|2019|686

Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival

|Cancer Research|2008|407

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

|Breast Cancer Research|2008|164

Polo-Like Kinase 1 Inhibition Kills Glioblastoma Multiforme Brain Tumor Cells in Part Through Loss of SOX2 and Delays Tumor Progression in Mice

|Stem Cells|2012|75

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)

|Oncotarget|2013|60